UNSPSC 51372002: Alletorphine

This classification denotes an opioid receptor agonist with the molecular formula C27H35NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4UWR086NOA, chemically known as 6,14-ethenotetrahydrooripavine, 17-allyl-17-demethyl-7alpha-((r)-1-hydroxy-1-methylbutyl)- but generally known as alletorphine, which bears US NIH Compound Identifier 72090. European Medicines Agency schedules Alletorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05333MIG.

UNSPSC 51372002 Alletorphine, a Commodity code, does not match the work actually being solicited under this code in recent state and local procurement activity. The three most recent opportunities tagged to this code involve naloxone procurement, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and exploratory market research on direct-to-manufacturer prescription programs — none of which involve alletorphine as a named pharmaceutical product. State and local governments show minimal or no recent purchasing activity under this specific commodity code. The mismatch suggests either misclassification in the source data or that alletorphine is not a material procurement target for state and local health agencies at this time.

The issuing bodies include Seminole County, Florida (health and safety procurement); the Minnesota Department of Administration acting on behalf of the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) with multi-state participation including Oregon; and the Texas Health and Human Services Commission (pharmaceutical benefit planning). Geographically, recent activity clusters in Florida, Minnesota, and Texas, with the MMCAP cooperative extending reach across multiple states. Representative opportunities include Seminole County's IFB60459723LAS (Naloxone & Drug Deactivation Systems, IFB, due July 26, 2023), MMCAP's S1070000015802 (generic pharmaceuticals and OTC products RFP, due March 26, 2026), and Texas HHS's RFI HHS0017013 (Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions, April 3, 2026). Given the absence of alletorphine-specific procurement signals, this code warrants careful verification before committing pursuit resources.